Core Insights - The announcement highlights the development of ASC30, a long-acting subcutaneous formulation of a small molecule GLP-1 receptor agonist, designed for weight maintenance therapy with a 75-day observed half-life, supporting quarterly dosing [1][2] Group 1: Clinical Research Findings - ASC30 demonstrated a median time to reach peak concentration (Cmax) of 17 days after a single 100 mg subcutaneous injection in obese subjects [1] - The drug showed a favorable gastrointestinal (GI) tolerance profile, with adverse events such as vomiting and nausea at 0.0%, and diarrhea and constipation at 12.5% in the ASC30 group, compared to higher rates in the placebo group [2] - No serious adverse events (SAE) or grade 3 and above adverse events (AE) were reported during the study, indicating a good safety profile [3] Group 2: Market Potential and Therapeutic Impact - ASC30 addresses a significant unmet medical need in long-term weight management, with the potential to improve patient adherence and quality of life through quarterly dosing [2] - The drug is positioned as a breakthrough in the field of weight maintenance therapy, being the fastest clinical advancement among quarterly dosing incretin medications [2] - ASC30 is the first and only small molecule GLP-1R agonist that can be administered orally daily or via subcutaneous injection monthly to quarterly, suitable for both weight loss and maintenance therapy [4]
歌礼制药-B：小分子GLP-1R激动剂ASC30用于减重维持的超长效皮下储库型制剂在肥胖受试者中显示出75天的表观半衰期